SKSnezana Kusljic

Snezana Kusljic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Snezana Kusljic has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: Novel pharmacological interventions in emotional and neuropsychiatric disorders

    by Alba Garcia-Baos, Tamara Timic Stamenic, Jenny L. Fiedler, Snezana Kusljic

    A recurring theme across the articles included in this Research Topic is the growing recognition that emotional and neuropsychiatric disorders arise from the dysregulation of interconnected biological systems rather than isolated neurotransmitter or neuroendocrine alterations. While serotonin, dopamine, and noradrenaline remain the central focus of current psychiatric treatments, increasing evidence indicates that developmental, genetic, and environmental factors dynamically shape their function. In this context, Palacios-Avedaño N et al. highlight that serotonergic function is profoundly influenced by developmental stage and biological sex, variables that have historically been overlooked in both preclinical and clinical research but are likely to contribute to differences in therapeutic efficacy. Consistent with this evolving view, novel receptor systems and neuromodulatory pathways that regulate emotional behavior have been identified beyond the classical monoaminergic hypothesis. Two original studies exemplified this concept through complementary investigations of cannabinoid-related signaling. Garcia-Gutierrez MS et al. demonstrated that loss of the non-canonical cannabinoid receptor GPR55 increased anxiety-and depression-like behaviors while altering amygdalar GABAAα2 receptor expression, highlighting a functional interaction between cannabinoid signaling and inhibitory neurotransmission in emotional regulation. Likewise, Zhu R et al. identified a circuit-specific mechanism through which endocannabinoid modulation influences depressive-like behaviors. Together, these findings reinforce the growing recognition that non-classical cannabinoid pathways constitute promising therapeutic targets (Cristino et al., 2019) and may provide new therapeutic avenues where conventional pharmacotherapies have shown limited efficacy. Zhang P et al. further emphasized the expanding complexity of receptor pharmacology. The authors discussed emerging evidence on sigma receptors as versatile modulators of neurotransmission, calcium homeostasis, synaptic plasticity, and neuroinflammatory responses, positioning them as attractive targets for next-generation antidepressant therapies. These contributions collectively underscore that understanding receptor biology requires considering cellular context, developmental timing, and individual biological variability if precision psychiatry is to become a clinical reality.A second major theme emerging from this Research Topic is the central role of neuroimmune regulation. Neuroinflammation is now recognized as a common mechanism across numerous psychiatric and neurological disorders, influencing synaptic function, neurotransmitter release, neuronal survival, and, lastly, behavioral outcomes (Bhatia et al., 2025). Zhang Y et al. showed that inhibition of the RhoA/NF-κB signaling pathway attenuated hippocampal inflammation while improving behavioral manifestations of post-stroke depression, providing mechanistic support for targeting inflammatory cascades in affective disorders. Similarly, Oka N et al. reported that administration of the human placental extract 'Melsmon' suppresses neuroinflammatory responses in both central and peripheral tissues induced by a stress-sensitive mouse model of depression. Although the interventions differ pharmacologically, these studies converge on the idea that targeting neuroimmune dysfunction represents a promising strategy for developing more effective treatments. Rather than acting in isolation, neuroimmune signaling interacts extensively with neurotransmission and neural circuitry. For example, inflammatory mediators influence glutamatergic and GABAergic transmission, endocannabinoid signaling, neurogenesis, and synaptic remodeling (Martins & Harrison, 2026), linking several of the mechanisms explored throughout this Research Topic.Beyond identifying novel therapeutic targets, another prominent feature of this collection is the increasing integration of systems biology into neuropsychopharmacology. Traditional drug discovery has often relied on approaches focusing on single molecular targets. In contrast, several contributions to this Research Topic adopted multidimensional strategies that integrate metabolomics, microbiome profiling, and biomarker discovery. Du Y et al. combined metabolomic and gut microbiota analyses to explore the therapeutic actions of levo-tetrahydropalmatine against ketamine addiction, illustrating how systems-level approaches can identify coordinated biological responses. Complementing these findings, the review by Pan J et al. points out microbial-mediated mechanisms linking gut microbiota dysbiosis to stress-related psychopathology, emphasizing the microbiome as a promising therapeutic target. Extending this perspective further, Rosas-Sanchez GU et al. discussed the emerging concept of personalized psychobiotics, proposing that targeted modulation of the gut microbiota may influence emotional regulation through coordinated effects on neurotransmitter synthesis, neuroimmune signaling, and the gut-brain axis. Together, these studies illustrate that integrating metabolic, microbial, and molecular information can improve our understanding of disease mechanisms at the molecular level and also facilitate the identification of novel therapeutic targets and biomarkers that influence treatment response. Such multidimensional strategies are likely to become progressively important as the field moves toward precision and personalized medicine. The review of Ochando et al. further reinforces the concept of precision medicine by summarizing recent advances in identifying molecular biomarkers associated with neurodevelopmental alterations following prenatal alcohol exposure. The identification of reliable biomarkers capable of predicting long-term neurological vulnerability represents a critical step toward earlier intervention and individualized patient management. Such efforts complement...

  • Open Access

    Connecting nursing cohorts in authentic learning activities through a redesigned pharmacology curriculum

    by Cik Yin Lee, Charne Miller, Elisa Bone, Snezana Kusljic


  • Open Access

    Reassessment of amphetamine- and phencyclidine-induced locomotor hyperactivity as a model of psychosis-like behavior in rats

    by Snezana Kusljic, Maarten van Den Buuse, Andrea Gogos

    Locomotor hyperactivity induced by psychotomimetic drugs, such as amphetamine and phencyclidine, is widely used as an animal model of psychosis-like behaviour and is commonly attributed to an interaction with dopamine release and N-methyl-D-aspartate (NMDA) receptors, respectively. However, what is often not sufficiently taken into account is that the pharmacological profile of these drugs is complex and may involve other neurotransmitter/receptor systems. Therefore, this study aimed to assess the effect of three antagonists targeting different monoamine pathways on amphetamine- and phencyclidine-induced locomotor hyperactivity. A total of 32 rats were pre-treated with antagonists affecting dopaminergic, noradrenergic and serotonergic transmission: haloperidol (0.05 mg/kg), prazosin (2 mg/kg) and ritanserin (1 mg/kg), respectively. After 30 min of spontaneous activity, rats were injected with amphetamine (0.5 mg/kg) or phencyclidine (2.5 mg/kg) and distance travelled, stereotypy and rearing recorded in photocell cages over 90 min. Pre-treatment with haloperidol or prazosin both reduced amphetamine-induced hyperactivity although pre-treatment with ritanserin had only a partial effect. None of the pre-treatments significantly altered the hyperlocomotion effects of phencyclidine. These findings suggest that noradrenergic as well as dopaminergic neurotransmission is critical for amphetamine-induced locomotor hyperactivity. Hyperlocomotion effects of phencyclidine are dependent on other factors, most likely NMDA receptor antagonism. These results help to interpret psychotomimetic drug-induced locomotor hyperactivity as an experimental model of psychosis.


  • Physical comorbidities in private psychiatric inpatients: Prevalence and its association with quality of life and functional impairment

    by Sarah E. Nadjidai, Snezana Kusljic, Nathan L. Dowling, Jennifer Magennis, Lisa Stokes, Chee H. Ng, Catherine Daniel

    The aim of this study was to examine the association between physical health conditions and quality of life and functioning in private psychiatric inpatients. We sought to determine whether quality of life and functioning was poorer in individuals with physical comorbidity compared to those without. A quantitative correlational descriptive design was utilized. Seventy patients were included in sequential order within a week of admission to hospital. Participants completed the SF‐36 survey, and the corresponding hospital records were audited. The STROBE guidelines were followed in the reporting of this research. The study found that 64.3% (45/70) of participants had one or more comorbid physical health conditions, primarily cardiovascular, respiratory, musculoskeletal, endocrine and medically unexplained conditions or syndromes. Chronic pain was experienced by 40% (28/70) of participants, and 47.6% (33/70) were found to be overweight or obese. Tobacco smoking and obesity were risk factors associated with physical comorbidity (P = 0.02 and P < 0.001, respectively). Quality of life and functioning were poorer in those with physical health conditions, particularly in the SF‐36 domains of bodily pain, physical functioning and general health (P < 0.001, P = 0.003 and P = 0.005, respectively). Physical health conditions were largely prevalent, and quality of life and functioning were poorer in those with physical comorbidities. The implementation of clinical guidelines for the monitoring of physical health has been proposed as well as a dedicated physical health nursing role. Continuation of integrative programmes focusing on both physical and mental health may also benefit patients in this setting.


  • Open Access

    The Impact of Removal of Ovarian Hormones on Cholinergic Muscarinic Receptors: Examining Prepulse Inhibition and Receptor Binding

    by Sarah S. Ch’ng, Adam J. Walker, Madeleine McCarthy, Thien-Kim Le, Natalie Thomas, Andrew Gibbons, Madhara Udawela, Snezana Kusljic, Brian Dean, Andrea Gogos

    Ovarian hormones, such as estrogens and progesterone, are known to exert beneficial effects on cognition and some psychiatric disorders. The basis of these effects is not fully understood, but may involve altered cholinergic neurotransmission. This study aimed to investigate how a lack of ovarian hormones would impact muscarinic receptor-induced deficits in prepulse inhibition (PPI) and muscarinic receptor density in several brain regions. Adult female rats were either ovariectomized, to remove the source of ovarian hormones, or left intact (sham-operated). PPI is a measure of sensorimotor gating that is typically impaired in schizophrenia patients, and similar deficits can be induced in rats by administering scopolamine, a muscarinic receptor antagonist. Our results revealed no significant effects of ovariectomy on PPI after saline or scopolamine treatment. Autoradiography was performed to measure cholinergic muscarinic receptor binding density using [3H]-pirenzepine, [3H]-AF-DX, and [3H]-4-DAMP, to label M1, M2/M4, and M3 receptors, respectively. We examined the amygdala, caudate putamen, dorsal hippocampus, motor cortex, retrosplenial cortex, and ventromedial hypothalamus. There were no significant group differences in any region for any muscarinic receptor type. These results suggest that removing peripheral ovarian hormones does not influence the cholinergic muscarinic receptor system in the context of PPI or receptor binding density.


  • Top Cited Papers
    Open Access

    Interventions to reduce medication errors in adult medical and surgical settings: a systematic review

    by Elizabeth Manias, Snezana Kusljic, Angela Wu

    Background and Aims: Medication errors occur at any point of the medication management process, and are a major cause of death and harm globally. The objective of this review was to compare the effectiveness of different interventions in reducing prescribing, dispensing and administration medication errors in acute medical and surgical settings. Methods: The protocol for this systematic review was registered in PROSPERO (CRD42019124587). The library databases, MEDLINE, CINAHL, EMBASE, PsycINFO, Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were searched from inception to February 2019. Studies were included if they involved testing of an intervention aimed at reducing medication errors in adult, acute medical or surgical settings. Meta-analyses were performed to examine the effectiveness of intervention types. Results: A total of 34 articles were included with 12 intervention types identified. Meta-analysis showed that prescribing errors were reduced by pharmacist-led medication reconciliation, computerised medication reconciliation, pharmacist partnership, prescriber education, medication reconciliation by trained mentors and computerised physician order entry (CPOE) as single interventions. Medication administration errors were reduced by CPOE and the use of an automated drug distribution system as single interventions. Combined interventions were also found to be effective in reducing prescribing or administration medication errors. No interventions were found to reduce dispensing error rates. Most studies were conducted at single-site hospitals, with chart review being the most common method for collecting medication error data. Clinical significance of interventions was examined in 21 studies. Since many studies were conducted in a pre–post format, future studies should include a concurrent control group. Conclusion: The systematic review identified a number of single and combined intervention types that were effective in reducing medication errors, which clinicians and policymakers could consider for implementation in medical and surgical settings. New directions for future research should examine interdisciplinary collaborative approaches comprising physicians, pharmacists and nurses. Lay summary: Activities to reduce medication errors in adult medical and surgical hospital areas Introduction: Medication errors or mistakes may happen at any time in hospital, and they are a major reason for death and harm around the world. Objective: To compare the effectiveness of different activities in reducing medication errors occurring with prescribing, giving and supplying medications in adult medical and surgical settings in hospital. Methods: Six library databases were examined from the time they were developed to February 2019. Studies were included if they involved testing of an activity aimed at reducing medication errors in adult medical and surgical settings in hospital. Statistical analysis was used to look at the success of different types of activities. Results: A total of 34 studies were included with 12 activity types identified. Statistical analysis showed that prescribing errors were reduced by pharmacists matching medications, computers matching medications, partnerships with pharmacists, prescriber education, medication matching by trained physicians, and computerised physician order entry (CPOE). Medication-giving errors were reduced by the use of CPOE and an automated medication distribution system. The combination of different activity types were also shown to be successful in reducing prescribing or medication-giving errors. No activities were found to be successful in reducing errors relating to supplying medications. Most studies were conducted at one hospital with reviewing patient charts being the most common way for collecting information about medication errors. In 21 out of 34 articles, researchers examined the effect of activity types on patient harm caused by medication errors. Many studies did not involve the use of a control group that does not receive the activity. Conclusion: A number of activity types were shown to be successful in reducing prescribing and medication-giving errors. New directions for future research should examine activities comprising health professionals working together.


  • How do cognitive and functional impairment relate to the use of anticholinergic medications in hospitalised patients aged 65 years and over?

    by Snezana Kusljic, Alexander Woolley, Matthew Lowe, Elizabeth Manias

    Anticholinergic medications are commonly prescribed to older adults despite their unfavourable pharmacological profile. There are no specific systems in place to alert prescribers about the wide range of medications with anticholinergic properties and their cumulative potential.